The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The group´s headquarter is located in Zwingenberg, South Hesse, Germany. Biocatalysts Ltd with several subsidiaries is a wholly-owned subsidiary of BRAIN Biotech AG.
FAQ - Frequently asked Questions
Here you’ll find answers to frequently asked questions about the BRAIN Biotech AG. If you have further questions, do not hesitate to contact us.
What is the relationship between BRAIN Biotech AG and the BRAIN Biotech Group?
When and where was BRAIN Biotech AG founded?
BRAIN Biotech AG has been founded in 1993 in Darmstadt, Germany.
When and where was BRAIN Biotech AG listed?
BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange since February 9th, 2016. (BNN; ISIN DE0005203947 / WKN 520394)
Why do you have registered shares?
Under the German Stock Corporation Act (Aktiengesetz), shares in a company are either in registered or in bearer form. Both forms of shares are prevalent in Germany and well established. Registered shares facilitate a better communication between the company and its stockholders and lead to improved transparency in regards to the company’s ownership structure.
What is BRAIN Biotech AG’s vision and mission?
Mission
We provide innovative biological solutions based on microorganisms and enzymes and enable more sustainable products and processes in industry with special enzymes, high-performance production strains and efficient bioprocesses.
We focus on the food, life science and environmental sectors.
Vision
As a service-provider and producer of enzyme specialties, we are aiming for a global top ten position among enzyme companies.
With our integrated offering for the development and production of enzymes, we are a sought-after partner and make an important contribution to the bioeconomy.
Our customized solutions and products have a positive impact on our partners’ competitiveness and sustainable industrial production.
What are BRAIN Biotech AG’s main products and services?
BRAIN Biotech AG focusses on the business-to-business (B2B) segment in industrial biotechnology. The corporate group develops and produces enzymes, proteins and microbial production strains for industrial applications with a focus on the food and beverage, health and life sciences and environmental sectors.
The Group divides its business activities into three operating segments plus a holding company. The level of innovation and scalability is reflected in two segments:
- BRAINBiocatalysts: development, production and distribution of specialty enzymes, microorganisms, ingredients
- BRAINBioIncubator: research-intensive development projects, pharmaceuticals
What is industrial biotechnology?
Industrial biotechnology contributes to more sustainable industrial processes and products. BRAIN Biotech AG provides biological solutions and products based on microorganisms and enzymes that enable industry to make their processes and products more sustainable.
Why is BRAIN Biotech AG an important contributor to the bioeconomy?
BRAIN Biotech is a market leader and trendsetter in the bioeconomy (bio-based economy). The concept of bioeconomy involves the use of biotechnology in the production of bio-based products. Our products and solutions directly address these United Nations´ SDGs: 2, 3, 6, 9 and 12.
What are "enzymes", "microorganisms" and "bioactive natural compounds"?
Enzymes are proteins, which are often industrially produced from microbes.
Enzymes catalyze specific biochemical reactions. This is why they are also called biocatalysts. Microorganisms (microbes) are living organisms, existing in single-celled form or in cell-colony form; for example, bacteria or fungi. They are industrially produced via fermentation in so-called bioreactors.
Bioactive natural compounds ("bioactives") are present in small quantities e.g. in foods like fruits, vegetables, and whole grains, and can provide health benefits beyond the basic nutritional value.
What does your Bioarchive collection include?
Our Bioarchive contains approximately 53,000 comprehensively characterized microorganisms, chassis microorganism strains for the development of production organisms and genetic libraries with new enzymes and metabolic pathways.
The collection is being expanded in ongoing projects and allows the identification of previously uncharacterized enzymes and new access to previously uncultivable microorganisms.
Are you planning to grow organically or through acquisitions?
Organic growth remains the primary driver of our strategy. We will continue to invest in our own product development and technological innovations, improving the speed, number of projects and innovations brought to market. In addition and for the time being, we currently focus on bolt-on acquisitions to add to our product offerings and improve economies of scale. By doing so, we will strive to best support our customers’ needs and to create value for our stakeholders.
Where can I find information on the BRAIN Biotech management?
Please have a look at the website section Management.
Can you explain BRAIN Biotech AG’s commitment to sustainability?
Please visit our website section Sustainability.
How is your financial year defined?
BRAIN Biotech AG’s fiscal year deviates from the calendar year. Our fiscal year starts on October 1st and ends on September 30th of the following year.
Where can I find the most recent financial update?
Please find BRAIN Biotech´s financial publications in the corresponding website section Financial Calendar & Publications
Which accounting standard does BRAIN Biotech Group use?
BRAIN Biotech Group deploys IFRS, International Financial Reporting Standards for its financial market communication.
Still have questions? Please do not hesitate to contact us.
You can also find explanations of technical terms in our glossary.
